Group 1 - Shengyi Electronics plans to repurchase shares with a total amount between 50 million and 100 million yuan, at a price not exceeding 43.02 yuan per share, for employee stock ownership plans [1] - Guoyao Modern's subsidiary has passed the consistency evaluation for the quality and efficacy of a generic drug, which is used for treating severe infections [1] - Tianhe Magnetic Materials' subsidiaries have obtained project filing notices for high-performance rare earth permanent magnet projects, with total investments of 100 million yuan and 50 million yuan respectively [1][2] Group 2 - Dream Lily intends to repurchase shares with an amount between 85 million and 170 million yuan, at a price not exceeding 10.90 yuan per share, supported by a loan commitment of up to 150 million yuan [3] - Weifu High-Tech has received a loan commitment of up to 135 million yuan from a financial institution for share repurchase [3] Group 3 - Lu'an Environmental Energy reported a coal sales volume of 4.51 million tons in April, a year-on-year increase of 17.75% [5] - *ST Tianshan reported a significant decline in livestock sales and revenue, with a revenue of 70,500 yuan in April, down 95.68% year-on-year [7] Group 4 - Feirongda announced a cash dividend of 0.38 yuan per 10 shares, with a total distribution of 21.9 million yuan [8] - Zhejiang Rongtai's shareholders and executives plan to reduce their holdings by up to 1.93% of the company's shares [9] Group 5 - Changhua Group's subsidiary won the land use rights for an industrial site in Ningbo for 27.05 million yuan, intended for manufacturing and related business [11] - Zejing Pharmaceutical's new drug application for a treatment for severe alopecia has been accepted by the regulatory authority [13][14] Group 6 - Hainan Mining plans to distribute a cash dividend of 0.8 yuan per 10 shares, totaling 1.59 billion yuan [15] - China Jushi plans to distribute a cash dividend of 0.24 yuan per share, totaling 9.61 billion yuan [16] Group 7 - Zhengzhong Design's subsidiary has obtained a utility model patent for an acrylic signage guide [18] - Rundu Co., Ltd. received approval for a veterinary drug product, which is intended for treating bacterial diseases in livestock [20] Group 8 - Emei Mountain A announced the resignation of its general manager due to work reasons [22] - Tonghua Dongbao's insulin injection has received a registration certificate in Nicaragua, allowing for sales in that market [23] Group 9 - Dizu Fashion's subsidiary has completed the registration of a private equity investment fund [24] - Ningbo Gaofa plans to increase capital by 60 million yuan in its subsidiary for operational needs [26] Group 10 - Haichuan Intelligent has obtained two utility model patents for material handling devices [27] - Newland's subsidiary signed a deep cooperation agreement with Alibaba Cloud for AI model applications [29] Group 11 - Rui Neng Technology's controlling shareholder plans to reduce its stake by up to 2.89% [30] - Guomai Culture intends to repurchase shares between 50 million and 100 million yuan for capital reduction [31] Group 12 - Shaanxi Construction won major construction projects totaling 7.88 billion yuan in April [32] - Hanyu Pharmaceutical signed a joint development agreement for a new peptide drug with a partner [34] Group 13 - Yunnan Copper is planning to acquire a 40% stake in Liangshan Mining, leading to a stock suspension [35] - Haizheng Pharmaceutical plans to repurchase shares between 50 million and 100 million yuan for employee stock ownership [36] Group 14 - Tianqiao Hoisting's controlling shareholder plans to increase its stake by 75 million to 150 million yuan [37] - Tiandi Online's controlling shareholder is transferring shares to introduce a strategic investor [38] Group 15 - Hongchang Technology plans to invest 15 million yuan in a joint venture with a partner [39] - Rabbit Baby's subsidiary is preparing for an IPO in Hong Kong [41] Group 16 - Wol Nuclear Materials is planning to issue H-shares for listing in Hong Kong [42] - Tangyuan Electric plans to raise up to 864 million yuan through a private placement for various projects [43] Group 17 - Tongrun Equipment's major shareholders plan to reduce their holdings by up to 2% [44] - Linzhou Heavy Machinery plans to raise up to 600 million yuan through a private placement [46] Group 18 - China Merchants Securities announced the resignation of its vice president [47] - Shangsheng Electronics plans to issue convertible bonds to raise up to 330 million yuan for various projects [48] Group 19 - Longda Co., Ltd.'s major shareholder plans to reduce its stake by up to 1% [49] - China Medical plans to acquire 100% of Jinsui Technology for 302 million yuan [50] Group 20 - Silek has signed a strategic cooperation agreement with a battery manufacturer [51] - Boyun New Materials' major shareholder plans to reduce its stake by up to 3% [53]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，上海现代制药股份有限公司（以下简称公司）全资子公司国药集团容 生制药有限公司（以下简称国药容生）收到国家药品监督管理局核准签发的《药 品补充申请批准通知书》，批准硫酸阿米卡星注射液通过仿制药质量和疗效一致 性评价（以下简称一致性评价）。现将相关情况公告如下： 一、药品基本信息 药品名称：硫酸阿米卡星注射液 剂型：注射剂 注册分类：化学药品 规格：2ml:0.2g（20 万单位）（按 C₂₂H₄₃N₅O₁₃计） 通知书编号：2025B02041 原药品批准文号：国药准字 H41020097 上市许可持有人：国药集团容生制药有限公司 药品生产企业：国药集团容生制药有限公司 申请事项：仿制药质量和疗效一致性评价 审批结论：根据《中华人民共和国药品管理法》、《国务院关于改革药品医 疗器械审评审批制度的意见》（国发〔2015〕44 号）、《关于仿制药质量和疗 效一致性评价工作有关事项的公告》（2017 年第 100 号）和《国家药监局关于 开展化学药品注射剂仿制药质量和疗效一致性评价 ...

| 代码 | 简称 | 今日涨跌幅 | 今日换手率 | 主力资金流量（万 | 主力资金净流入比率 | | --- | --- | --- | --- | --- | --- | | | | （%） | （%） | 元） | （%） | | 300740 | 水羊股 份 | 7.34 | 11.92 | 1365.96 | 2.37 | | 002762 | *ST金 比 | 1.87 | 6.12 | 764.00 | 12.09 | | 002172 | 澳洋健 康 | -1.64 | 5.20 | 490.76 | 3.40 | | 600572 | 康恩贝 | 0.00 | 0.81 | 453.06 | 4.92 | | 002566 | 益盛药 业 | 0.56 | 2.84 | 449.27 | 9.45 | | 000516 | 国际医 学 | -2.10 | 1.02 | 173.25 | 1.49 | | 603139 | 康惠制 | -1.57 | 1.79 | -62.03 | -1.77 | | | 药 | | | | | | 000615 | *ST 美 | 0.63 | 1.59 ...

证券代码：600420 证券简称：国药现代 公告编号：2025-038 上海现代制药股份有限公司 关于参加 2025 年上海辖区上市公司年报集体业绩说明会 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 投资者可于 2025 年 5 月 9 日（星期五）至 5 月 14 日（星期三）16:00 前，登录上证路演中心网站首页，点击"提问预征集"栏目或通过公司邮箱 xd_zhengquanban@sinopharm.com 进行提问。公司将在说明会上对投资者普遍关 注的问题进行回答。 上海现代制药股份有限公司（以下简称公司）已于 2025 年 3 月 28 日及 2025 年 4 月 29 日分别发布了《2024 年度报告》及《2025 年第一季度报告》。为便于 广大投资者更全面深入地了解公司经营成果、财务状况，公司计划于 2025 年 5 月 15 ...

Core Viewpoint - The company, Shanghai Modern Pharmaceutical Co., Ltd., announced that its wholly-owned subsidiary, National Pharmaceutical Group Rongsheng Pharmaceutical Co., Ltd., has received approval for potassium chloride injection to pass the consistency evaluation of generic drug quality and efficacy, which is expected to enhance market expansion and sales potential for the product [6][7]. Financial Data - The quarterly financial report for the first quarter of 2025 has not been audited [3]. - The company has invested approximately RMB 1.6354 million in the research and development of potassium chloride injection [8]. Drug Information - Potassium chloride injection is a commonly used medication for supplementing potassium in the body, primarily used to treat and prevent hypokalemia, especially when oral supplementation is not possible [7]. - The sales revenue of potassium chloride injection in public medical institutions across China was RMB 619 million in 2023 [7]. Regulatory Approval - The approval was granted based on various regulations, including the Drug Administration Law of the People's Republic of China and related announcements regarding the consistency evaluation of generic drugs [6].

Financial Performance - The company reported a basic earnings per share of 0.2695 yuan for Q1 2025, representing a 9.11% increase compared to 0.2470 yuan in Q1 2024 and a significant rise from 0.1529 yuan in Q1 2023 [1] - The net profit for Q1 2025 was 3.61 billion yuan, up 9.06% from 3.31 billion yuan in Q1 2024 and a substantial increase from 1.79 billion yuan in Q1 2023 [1] - Operating revenue decreased to 26.07 billion yuan in Q1 2025, down 16.52% from 31.23 billion yuan in Q1 2024 and also lower than 34.17 billion yuan in Q1 2023 [1] - The return on equity (ROE) improved to 2.70% in Q1 2025 from 2.64% in Q1 2024 and 1.72% in Q1 2023 [1] Shareholder Structure - The top ten unrestricted shareholders collectively hold 82,576.74 million shares, accounting for 61.56% of the circulating shares, which is a decrease of 2,664.93 million shares from the previous period [1] - Shanghai Pharmaceutical Industrial Research Institute Co., Ltd. remains the largest shareholder with 23,951.26 million shares, representing 17.86% of the total share capital, unchanged from the previous report [2] - China Pharmaceutical Investment Co., Ltd. and China National Pharmaceutical Group Corporation also maintained their holdings at 17,400.56 million shares (12.97%) and 15,309.16 million shares (11.41%), respectively [2] Dividend Policy - The company has announced that it will not distribute dividends or transfer shares in the current period [3]

证券代码：600420 证券简称：国药现代 公告编号：2025-037 一、药品基本信息 药品名称：氯化钾注射液 剂型：注射剂 注册分类：化学药品 规格：10ml:1.5g 证书编号：2025B01844 上海现代制药股份有限公司 关于全资子公司药品通过仿制药一致性评价的自愿性信息 披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，上海现代制药股份有限公司（以下简称公司）全资子公司国药集团容 生制药有限公司（以下简称国药容生）收到国家药品监督管理局核准签发的《药 品补充申请批准通知书》，批准氯化钾注射液通过仿制药质量和疗效一致性评价 （以下简称一致性评价）。现将相关情况公告如下： 证券代码：600420 证券简称：国药现代 公告编号：2025-037 米内网数据库显示，氯化钾注射液 2023 年全国公立医疗机构销售额为人民 币 6.19 亿元。根据 CDE 网站显示，目前氯化钾注射液通过/视同通过一致性评价 的企业还有湖北科伦药业有限公司、海南景泽康生物科技有限公司、南京赛瑞谱 顿制药有限公司、石家庄四药有限公司 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥2,606,778,071.34, a decrease of 16.54% compared to ¥3,123,407,807.27 in the same period last year[5] - Net profit attributable to shareholders was ¥361,413,759.19, representing a year-on-year increase of 9.10% from ¥331,257,150.18[5] - Basic and diluted earnings per share increased to ¥0.2695, up 9.11% from ¥0.2470 in the same period last year[5] - Operating profit for Q1 2025 was ¥509,056,478.60, slightly decreased from ¥524,600,367.61 in Q1 2024[18] - In Q1 2025, the net profit was approximately ¥423.54 million, a slight decrease of 0.6% compared to ¥425.86 million in Q1 2024[19] - The net profit attributable to the parent company increased to ¥361.41 million, up 9.1% from ¥331.26 million in the same period last year[19] Cash Flow and Investments - The net cash flow from operating activities decreased by 57.15%, amounting to ¥304,807,330.15, down from ¥711,404,907.55 in the previous year[5] - Cash flow from operating activities in Q1 2025 was ¥304.81 million, down 57.1% from ¥711.40 million in Q1 2024[21] - Total cash inflow from operating activities decreased to ¥2.21 billion, a decline of 29.5% from ¥3.14 billion in the previous year[21] - The company reported a net cash outflow from investing activities of approximately ¥337.87 million in Q1 2025, compared to a net outflow of ¥185.26 million in Q1 2024[22] - The company received cash of ¥1.06 billion related to investment activities in Q1 2025, indicating a significant increase in cash inflow from investments[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥19,328,793,560.17, a decrease of 3.14% from ¥19,955,597,470.69 at the end of the previous year[5] - Total liabilities decreased to ¥3,583,289,440.24 as of March 31, 2025, from ¥4,633,633,097.68 at the end of 2024[15] - Cash and cash equivalents were ¥5,109,086,433.09 as of March 31, 2025, down from ¥6,211,941,467.03 at the end of 2024[13] - Inventory as of March 31, 2025, was ¥2,091,351,135.35, a decrease from ¥2,208,799,259.06 at the end of 2024[13] - Non-current assets totaled ¥8,400,755,287.40 as of March 31, 2025, an increase from ¥8,271,493,346.47 at the end of 2024[14] Shareholder Information - The company had a total of 40,821 common shareholders at the end of the reporting period[10] - The largest shareholder, Shanghai Pharmaceutical Industry Research Institute Co., Ltd., held 239,512,622 shares, accounting for 17.86% of total shares[11] - The company did not report any significant changes in shareholder participation in financing or securities lending activities during the period[12] Other Financial Metrics - The weighted average return on net assets increased to 2.70%, up by 0.06 percentage points from 2.64%[5] - Non-recurring gains and losses totaled ¥15,146,012.94 for the period, with significant contributions from government subsidies and fair value changes of financial assets[7] - The company reported an investment income of ¥20,681,510.13 in Q1 2025, significantly higher than ¥2,479,299.44 in Q1 2024[18] - The impact of exchange rate changes on cash and cash equivalents was a positive ¥12.18 million in Q1 2025, compared to ¥2.50 million in Q1 2024[22]

证券代码：600420 证券简称：国药现代 公告编号：2025-035 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，上海现代制药股份有限公司（以下简称公司）全资子公司国药集团工 业有限公司（以下简称国药工业）、控股子公司国药一心制药有限公司（以下简 称国药一心）分别收到国家药品监督管理局核准签发的《药品注册证书》。现将 相关情况公告如下： 一、富马酸喹硫平缓释片 （一）药品基本信息 药品名称：富马酸喹硫平缓释片 剂型：片剂 规格：200mg（按 C₂₁H₂₅N₃O₂S 计） 注册分类：化学药品 4 类 上海现代制药股份有限公司 关于下属子公司获得药品注册证书的公告 证书编号：2025S01096 药品批准文号：国药准字 H20253944 上市许可持有人：国药集团工业有限公司 药品生产企业：国药集团工业有限公司 申请事项：药品注册（境内生产） 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。 （二）药品研发及市场情况 富马酸喹硫平是一种调节脑神经 ...

Core Insights - The company announced that its wholly-owned subsidiary, China National Pharmaceutical Group Industrial Co., Ltd., and its controlling subsidiary, China National Pharmaceutical Yixin Pharmaceutical Co., Ltd., have obtained drug registration certificates for two medications: Fumaric Acid Quetiapine Sustained-Release Tablets and Capecitabine Tablets [1] Group 1: Drug Registration and Sales - Fumaric Acid Quetiapine Sustained-Release Tablets are primarily used for the treatment of schizophrenia and bipolar disorder, with sales in public hospitals and urban pharmacies reaching 445 million yuan in 2023 [1] - Capecitabine Tablets are indicated for metastatic colorectal cancer, achieving sales of 164 million yuan in public hospitals and urban pharmacies in 2023 [1] Group 2: R&D Investment - China National Pharmaceutical Group Industrial Co., Ltd. and China National Pharmaceutical Yixin Pharmaceutical Co., Ltd. have made cumulative R&D investments of approximately 16.32 million yuan and 27.50 million yuan, respectively [1]